TPD52 and neoplasm: Consistent with this idea, multiple studies have confirmed the overexpression of TPD52 in several cancers.[12, 13, 14, 15, 16] Recently, we convincingly showed that TPD52 isoform 1 acts as a potential proto‐oncogene by activating the chaperone‐mediated autophagy pathway.[17] In contrast, TPD52 was identified as a potential tumor suppressor in hepatocellular carcinoma.[18] These inconsistent findings indicate a cell‐ or tissue‐context‐dependent function of TPD52 in the malignant progression of cancer.